Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M18.6Revenue $M8.0Net Margin (%)-133.3Altman Z-Score-84.9
Enterprise Value $M17.3EPS $-6.4Operating Margin %-131.4Piotroski F-Score4
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-133.3Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.3Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %0.1Current Ratio0.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-1,099.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M1.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

OPNT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5177.14view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5177.14view
COHEN MARC AChairman,CEO,Treas, & Sec, 10% Owner 2012-06-14Sell24,323$24.5-60.41view
KAISER RONALD WDirector 2012-06-06Sell10,000$26.04-62.75view
KAISER RONALD WDirector 2010-12-08Sell10,000$26.08-62.81view
Wesley Melvin IIICFO 2010-11-29Sell1,053$24.24-59.98view
Wesley Melvin IIICFO 2010-11-18Sell2,309$21.9-55.71view
COHEN ALAIN JPresident & Chief Tech Officer, 10% Owner 2010-07-27Sell230$15.15-35.97view
COHEN MARC AChairman, CEO, Treas, & Sec, 10% Owner 2010-07-27Sell250$15.15-35.97view
Wesley Melvin IIICFO 2010-07-27Sell74$15.15-35.97view

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 02 2016
Government Spending On Opioid Epidemic Creates Surprising Beneficiary Apr 28 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 15 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2016 By the Numbers Mar 22 2016
FDA Approved This Drug for an Unmet Need That Is Now 21x Larger Than Previously Thought Mar 21 2016
OPIANT PHARMACEUTICALS, INC. Financials Mar 19 2016
Opiant Pharmaceuticals, Inc., Reports Fiscal Second Quarter 2016 Financial Results and Provides... Mar 16 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Mar 15 2016
Opiant Pharmaceuticals, Inc., Announces Ticker Symbol Change to “OPNT” Mar 07 2016
Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma... Mar 07 2016
Billions Invested in Cyber Security Explain Opportunity for Opioid Antidote Feb 26 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security... Feb 17 2016
Opiant Pharmaceuticals, Inc., Convenes Medical Advisory Board to Support Development of... Feb 17 2016
Lightlake Therapeutics Inc. Announces Name Change to Opiant Pharmaceuticals, Inc. Feb 17 2016
Lightlake Therapeutics Inc. Expands Drug Development Capabilities by Appointing Mark Ellison, Ph.D.,... Feb 16 2016
OPIANT PHARMACEUTICALS, INC. Financials Feb 06 2016
Could This Company Be The Best Way To Capitalize On Opioid Crisis? Jan 25 2016
Traders Look to Upside - Complementary Research on Kingfisher, Lafargeholcim, Yahoo Japan and... Jan 20 2016
Rite Aid, CVS, Obama Create Momentum For This Company's New Drug Launch Jan 12 2016
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan®... Jul 30 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)